Table 1.
Summary of the studies' characteristics included in the analysis.
| First Author | Research Method | Center | Study Time | Site of GEC | Included Nodules |
|---|---|---|---|---|---|
| Alexander et al.[7] | P | Multi Centers | 2011.1-2012.8 | Veracyte Inc | 567 |
| Sacks et al.[12] | R | Single Center | 2012.1-2014.12 | tertiary | 567 |
| Chaudhary et al.[13] | R | Single Center | 2009.7-2015.1 | Veracyte Inc | 158 |
| Harrell et al.[14] | U | Single Center | 2011.1-2013.4 | Veracyte Inc | 58 |
| Harrison et al.[15] | R | Single Center | 2013.8-2015.3 | Veracyte Inc | 115 |
| El Hussein et al.[16] | R | Single Center | 2012.1-2016.7 | Veracyte Inc | 227 |
| Abeykoon et al.[17] | R | Single Center | 2014.12-2015.2 | Veracyte Inc | 34 |
| Noureldine et al.[18] | R | Single Center | 2012.1-2014.12 | Veracyte Inc | 273 |
| McIver et al.[19] | P | Multi Centers | 2011.5-2012.12 | Veracyte Inc | 105 |
| Marti et al.[20] | R | Multi Centers | 2013.2-2014.12 | Veracyte/tertiary | 165 |
| Lastra et al.[21] | R | Single Center | 2011.2-2014.1 | Veracyte Inc | 132 |
| Alexander et al.[22] | R | Multi Centers | 2010.9-2013.1 | Veracyte Inc | 339 |
| Yang et al.[23] | R | Single Center | 2012.8-2014.4 | Veracyte Inc | 187 |
| Celik et al.[24] | P | Single Center | 2011.12-2014.7 | Veracyte Inc | 66 |
| Al-Qurayshi et al.[25] | R | Single Center | 2013.1-2016.2 | tertiary | 154 |
| Samulski et al.[26] | R | Single Center | 2011.1-2015.12 | U | 294 |
| Kay-Rivest et al.[27] | R | Multi Centers | 2013.?-2015.? | Veracyte Inc | 172 |
| Han et al.[28] | R | Single Center | 2009.8-2013.3 | U | 114 |
GEC, gene expression classifier; R: retrospective; P: prospective; U: unclear.